Bioarctic and Eisai target protofibrils in Alzheimer’s disease
By Cormac Sheridan
Tuesday, March 4, 2014
STOCKHOLM – The vexed problem of conclusively proving – or disproving – the amyloid hypothesis as the key driver of the pathology of Alzheimer’s disease has been exhaustively rehearsed in multiple settings over the last decade.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.